SCHEMBL363193

SCHEMBL363193

O=C(O)c1c[nH]cc(-c2ccc(F)cc2)c1=O

nearest known ligand 0.48

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
KDM4E B2RXH2 2/20 0.46
BCL2L1 Q07817 1/20 0.44
BAD Q92934 1/20 0.44
GPR35 Q9HC97 2/20 0.43
ALDH1A1 P00352 3/20 0.42
KMT2A Q03164 2/20 0.42
AURKB Q96GD4 1/20 0.40
MET P08581 3/20 0.40
KDR P35968 1/20 0.40
MEN1 O00255 1/20 0.40
USP2 O75604 1/20 0.40
DHFR P00374 1/20 0.40
CA1 P00915 1/20 0.40
CA2 P00918 1/20 0.40
LMNA P02545 1/20 0.40
TTR P02766 1/20 0.40
ALB P02768 1/20 0.40
HMGB1 P09429 1/20 0.40
HPGD P15428 1/20 0.40
CXCL12 P48061 1/20 0.40

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL14705876 0.87 ALDH1A1 (0.49) KDM4EBCL2L1BADGPR35ALDH1A1
SCHEMBL17233734 0.85 AURKB (0.42) KDM4EBCL2L1BADALDH1A1AURKB
SCHEMBL29757272 0.85 IKBKB (0.43) KMT2AAURKBMETKDRMEN1
SCHEMBL319126 0.84 ALDH1A1 (0.58) KDM4EALDH1A1KMT2AMEN1
SCHEMBL21176862 0.83 PRKAB2 (0.48) KDM4EALDH1A1KMT2AUSP2HPGD
SCHEMBL15334363 0.81 SLC6A3 (0.59) KDM4EALDH1A1KMT2AAURKBMET
SCHEMBL18256953 0.81 IKBKB (0.47) KDM4EALDH1A1KMT2AAURKBMET
SCHEMBL23158698 0.79 NR4A2 (0.38) KDM4EBCL2L1BADALDH1A1AURKB
SCHEMBL699308 0.77 PRKCZ (0.49) KDM4EALDH1A1KMT2AMEN1LMNA
SCHEMBL22210777 0.77 AURKB (0.42) KDM4EALDH1A1KMT2AAURKBMET

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 91 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-2867223-B1 NOVEL FUSED PYRIDINE DERIVATIVES USEFUL AS c-MET TYROSINE KINASE INHIBITORS BETTA PHARMACEUTICALS CO LTD (CN) 2018-09-05 EP claimed
US-9617257-B2 Fused pyridine derivatives useful as c-Met tyrosine kinase inhibitors BETTA PHARMACEUTICALS CO., LTD (CN) 2017-04-11 US claimed
EP-2593462-B1 NOVEL FUSED HETEROCYCLIC DERIVATIVES USEFUL AS C-MET TYROSINE KINASE INHIBITORS BETTA PHARMACEUTICALS CO LTD (CN) 2016-09-07 EP claimed
US-9242991-B2 Substituted fused heterocycles as c-Met tyrosine kinase inhibitors BETTA PHARMACEUTICALS CO., LTD (CN) 2016-01-26 US claimed
US-20150315210-A1 NOVEL FUSED PYRIDINE DERIVATIVES USEFUL AS c-MET TYROSINE KINASE INHIBITORS BETTA PHARMACEUTICALS CO., LTD. (CN) 2015-11-05 US claimed
US-20130123286-A1 Novel Fused Heterocyclic Derivatives Useful as c-Met Tyrosine Kinase Inhibitors BETTA PHARMACEUTICALS CO., LTD. (CN) 2013-05-16 US claimed
US-12371428-B2 Pyridone compounds and methods of use EXELIXIS, INC. (US) 2025-07-29 US disclosed
WO-2024251182-A1 QUINOXALINE COMPOUND AND USE THEREOF 广州六顺生物科技有限公司 2024-12-12 WO disclosed
CN-119101036-A Quinoxaline compound and application thereof 广州六顺生物科技有限公司 2024-12-10 CN disclosed
CN-114907339-B 4- (4-aminophenoxy) pyridin-2-amine derivatives and use thereof 成都奥睿药业有限公司 2023-07-14 CN disclosed
CN-114716440-B Pyrrolotriazine derivatives, and preparation method and application thereof 广州六顺生物科技股份有限公司 2023-06-30 CN disclosed
US-20230203029-A1 NAPHTHYRIDINE COMPOUNDS AS INHIBITORS OF MER TYROSINE KINASE AND AXL TYROSINE KINASE EVOTEC (UK) LIMITED (GB) 2023-06-29 US disclosed
EP-4126238-A1 NAPHTHYRIDINE COMPOUNDS AS INHIBITORS OF MER TYROSINE KINASE AND AXL TYROSINE KINASE Kinsensus Limited (GB) 2023-02-08 EP disclosed
CN-101977906-A 4-pyridinone compounds and their use for cancer BRISTOL MYERS SQUIBB CO 2011-02-16 CN disclosed
CN-101977905-A 4-pyridinone compounds and their use for cancer BRISTOL MYERS SQUIBB CO 2011-02-16 CN disclosed
WO-2011017142-A1 NOVEL BICYCLIC UREA COMPOUNDS MERCK PATENT GMBH (DE) 2011-02-10 WO disclosed
US-20110034416-A1 4-PYRIDINONE COMPOUNDS AND THEIR USE FOR CANCER BRISTOL-MYERS SQUIBB COMPANY 2011-02-10 US disclosed
US-20110034416-A1 4-PYRIDINONE COMPOUNDS AND THEIR USE FOR CANCER BRISTOL-MYERS SQUIBB COMPANY 2011-02-10 US disclosed
WO-2009094417-A1 4-PYRIDINONE COMPOUNDS AND THEIR USE FOR CANCER BRISTOL-MYERS SQUIBB COMPANY (US) 2009-07-30 WO disclosed
WO-2009094427-A1 4-PYRIDINONE COMPOUNDS AND THEIR USE FOR CANCER BRISTOL-MYERS SQUIBB COMPANY (US) 2009-07-30 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20110034416-A1 4-PYRIDINONE COMPOUNDS AND THEIR USE FOR CANCER DPYD, CDK4, G6PD KDM4E 1712/4885BCL2L1 2693/4885BAD 2020/4885
US-20150315210-A1 NOVEL FUSED PYRIDINE DERIVATIVES USEFUL AS c-MET TYROSINE KINASE INHIBITORS MET, ABL1, ROS1 KDM4E 900/4885BCL2L1 2253/4885BAD 3309/4885
US-12371428-B2 Pyridone compounds and methods of use PDXK, PLK2, MAP4K2 KDM4E 2816/4885BCL2L1 3877/4885BAD 3025/4885
US-20130123286-A1 Novel Fused Heterocyclic Derivatives Useful as c-Met Tyrosine Kinase Inhibitors MET, RET, ABL1 KDM4E 1318/4885BCL2L1 2420/4885BAD 3578/4885
US-20230203029-A1 NAPHTHYRIDINE COMPOUNDS AS INHIBITORS OF MER TYROSINE KINASE AND AXL TYROSINE KINASE MERTK, AXL, TYRO3 KDM4E 2105/4885BCL2L1 1004/4885BAD 1732/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.